CAR T-cell therapy improves survival in relapsed or refractory lymphoma

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...
Medscape

NICE Approves CAR T-Cell Therapy for Patients With Lymphoma

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...
MedPage Today

'Armored' CAR T Cells Highly Active in Lymphoma After Prior CAR-T Failure

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...
Post and Courier

Lymphoma patients have better shot at fighting hard-to-beat cancers with MUSC's new cell therapy

Anthony Cannella had twice faced down a rare and aggressive cancer only to see it come back a number of years later. The third time might be the charm for him after he received a refined therapy that ...